AtaiBeckley’s MDMA drug shows positive Phase IIa results in social anxiety disorder

New York-based AtaiBeckley (NASDAQ: ATAI) announced topline results from its exploratory Phase IIa trial evaluating EMP-01, an oral R-MDMA candidate, in adults with social anxiety disorder. The readout marks the first clinical dataset for a single-enantiomer R-MDMA compound tested in this patient population, and arrives at a time when the broader field of MDMA psychedelic therapy faces continued regulatory uncertainty following the US FDA’s 2024 rejection of racemic MDMA for post-traumatic stress disorder.

Trial specifics

The study was a multi-center, randomized, double-blind, placebo-controlled, first-in-patient Phase IIa trial conducted across seven clinical sites in the United Kingdom. It enrolled 71 adults with moderate-to-severe social anxiety disorder, of whom 70 received at least one dose and 69 completed the Day 43 efficacy assessments. Participants were randomized to receive either two in-clinic oral administrations of EMP-01 at 225 mg or matching placebo, spaced 28 days apart, with no adjunctive psychotherapy provided. All clinician-rated assessments were performed by blinded central raters. The enrolled population was severely affected, with a mean baseline Liebowitz Social Anxiety Scale (LSAS) score of approximately 108 out of a possible 144.

The primary endpoint was safety and tolerability through Day 43. On this measure, EMP-01 met its objective: no serious adverse events were reported, no treatment-emergent suicidal behavior or intent was observed, and most adverse events were mild or moderate and resolved without intervention. The secondary endpoint was change in social anxiety symptoms from baseline to Day 43 on the LSAS, a 24-item clinician-rated instrument assessing both fear responses and avoidance behaviors across social and performance situations. EMP-01 produced a least squares mean reduction of 28.53 points versus 16.67 points for placebo, yielding a placebo-adjusted difference of 11.85 points (Hedges’ g = 0.45; p = 0.036, one-tailed). The company noted the study was not powered for statistical significance. On the exploratory Clinician Global Impression–Improvement (CGI-I) scale, 49% of EMP-01-treated patients were rated as “very much improved” or “much improved” compared with 15% on placebo, corresponding to a number needed to treat of 2.95 (95% CI: 1.84–7.42). AtaiBeckley also reported that EMP-01 produced parallel reductions in both the Fear and Avoidance sub-domains of the LSAS, a pattern the company characterized as unusual given that avoidance behaviors typically change more slowly than fear responses in social anxiety disorder treatment trials.

Srinivas Rao, chief executive officer and co-founder of AtaiBeckley, said the company would present more detailed analyses at upcoming scientific venues and that the data would “guide subsequent development.” The company did not disclose a specific timeline for advancing EMP-01 into later-stage trials or identify a regulatory filing pathway. AtaiBeckley’s broader pipeline includes BPL-003 (mebufotenin benzoate nasal spray) in Phase III planning for treatment-resistant depression and VLS-01 (DMT buccal film) in Phase II for the same indication.

Research context

EMP-01 is the R-enantiomer of MDMA, formulated as an oral hydrochloride salt. Racemic MDMA acts primarily by promoting the release of serotonin, norepinephrine, and dopamine through reversal of their respective monoamine transporters, with downstream effects on oxytocin release and modulation of amygdala reactivity to social threat cues. AtaiBeckley has designed EMP-01 as a single-enantiomer formulation intended to retain the entactogenic and pro-social pharmacology attributed to the R-enantiomer while reducing dopaminergic and noradrenergic activity relative to the racemic mixture. The rationale for this approach in social anxiety disorder rests on the hypothesis that R-MDMA may attenuate fear-driven social avoidance and alter affective processing of social threat without requiring daily dosing or concurrent psychotherapy, a model explored in prior mechanistic literature.

Social anxiety disorder affects an estimated 30 million adults in the United States alone, with a lifetime prevalence of approximately 12%. Current first-line pharmacotherapy consists of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), which require daily administration for 8 to 12 weeks before full effect and leave roughly half of treated patients without adequate response. No new pharmacological class has been approved for social anxiety disorder in over two decades, and cognitive behavioral therapy, while effective, faces access and scalability constraints.

The oral R-MDMA clinical trial for EMP-01 in social anxiety enters a field with limited active competition. The most directly comparable program is a completed Phase II study of racemic MDMA-assisted therapy in social anxiety disorder, which was conducted independently and has reported results. No other active or recruiting interventional trials specifically targeting social anxiety disorder with MDMA or related entactogens were identified in clinical trial registries at the time of the AtaiBeckley Phase IIa results announcement. The broader MDMA psychedelic therapy landscape remains shaped by the US FDA’s August 2024 Complete Response Letter to Lykos Therapeutics for midomafetamine (racemic MDMA) in PTSD, a decision that raised questions about the regulatory pathway for MDMA-based compounds and the evidentiary standards applied to psychedelic-assisted treatment models. AtaiBeckley’s approach with EMP-01 differs from the Lykos program in two respects: it uses a single enantiomer rather than the racemate, and it does not pair drug administration with structured psychotherapy sessions.

Whether the AtaiBeckley Phase IIa results, generated in a 71-patient UK-based trial without psychotherapy, will translate into a registrational program capable of satisfying US FDA requirements remains an open question. The company has not yet disclosed its Phase IIb or Phase III strategy, and the one-tailed statistical test used for the secondary efficacy endpoint will likely draw scrutiny from regulators and the clinical community as more detailed data emerge.